re: one of these Cephalon valued the co at $4.85 two years ago with little revenues and not much profits, 20 US centers, no Australian reimburrsemeent, and early clinical trials. Now the co has 75 US centers , doubling last years revenues, highly profitable with high margins , New US plant built and coming on line, 4 new chemio drugs that work with Sir spheres synergistally, 4 major pharma collaborations, Australian reimbursement this quarter, and expanding indications for the product. THis is most definitely worth 9-11 to one of many bidders.
genentech inc., page-9
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.05M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.5¢ | 12.5¢ | $10.02K | 77.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 871877 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 1842483 | 5 |
View Market Depth
| Last trade - 15.40pm 20/06/2024 (20 minute delay) ? |
| SRX (ASX) Chart |